Company intelligence / Profile preview

RION

Rochester, Minnesota, United Statesriontx.com ↗
Ownership
Private
Employees
~100
Development stage
Other
01

Overview

Currently conducting a Phase 1b clinical study for Knee Osteoarthritis with their Purified Exosome Product (PEP™). The study will enroll 24 patients across the United States to evaluate safety, tolerability, and preliminary efficacy, including signals of cartilage regeneration and inflammation reduction[5].

Therapeutic areas
PulmonologyCardiovascularDermatologyRheumatology
Modalities
Exosome therapeutics
Industry
Biotech
02

Drug pipeline

13 assets

Platelet-Derived Exosomes IV Infusion

1

12 more assets in the full pipeline.

03

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on RION.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RION.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call